ABBVIE INC — FDA ORIG Approval for JUVMO (Not disclosed in the FDA record.)

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows ABBVIE INC as the sponsor of JUVMO, with the generic name recorded as unspecified and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220415, with a submission status date of 20260925. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

AbbVie Inc.’s FDA history

Argus HQ has recorded 5 total FDA actions tied to AbbVie Inc.: 0 warning letters, 4 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What did FDA approve?

FDA's record shows nda approval for JUVMO (unspecified), dosage form TABLET, sponsored by ABBVIE INC, under application number NDA220415. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Is this product available now?

FDA's record lists a submission status date of 20260925. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does ABBVIE INC have other FDA approval records?

Yes. Argus HQ has recorded 5 total FDA actions tied to ABBVIE INC, including 1 approval record.

Related enforcement actions

• Approval (recent): UPSHER SMITH LABS — ANDA approval: PREDNISOLONE ACETATE (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: METRONIDAZOLE (unspecified) →
• Approval (recent): TEVA PHARMACEUTICALS, INC. — BLA approval: DEGEVMA (unspecified) →
• Approval (recent): BRISTOL — NDA approval: CAMZYOS (unspecified) →
• Approval (recent): INCYTE CORP — NDA approval: ATEBRIOZ (unspecified) →
• Approval (recent): AZURITY PHARMACEUTICALS INC — NDA approval: Unspecified (unspecified) →
• Approval (recent): ADVENTAPHARMA DWC LLC — NDA approval: ZUEINO (unspecified) →
• Approval (recent): NEPHRON — ANDA approval: DEXMEDETOMIDINE HYDROCHLORIDE (unspecified) →